PPT-Comparison of US/EU Biosimilar

Guidelines Kamali Chance MPH PhD RAC Senior Director Head Global Biosimilars Regulatory Strategy Definition of Biosimilarity Biosimilar Guidelines Issuance in the EU and US Regulation . biosimilar. . ?. David Lim, Julie Hepworth, Lisa Nissen. c113.lim@qut.edu.au. CC-BY,NC Sarah Macmillan. Biotech . protein. Biotech . drug. Biopharmaceutical. Follow-on biologic . product < . 生. RPh. Safe School Meds, Principle Partner. Moffitt Cancer Center, Director of Pharmacy (Retired). Biosimilar Drugs: . Opportunities and Issues. The Community Oncology Alliance Conference. Moving Forward on Payment Reform. OMIC Group Biosimilars 2014. Hyderabad India. 27-29 Oct 2014. Rodeina Challand. ChallandRodeina@prahs.com. Global Biosimilar Concept. Generic approach is not appropriate. Step-wise comparability approach. Professor of Medicine. Cleveland Clinic Lerner College of Medicine . RJ . Fasenmyer. Chair of Clinical Immunology. Cleveland Clinic. Cleveland, Ohio. Edward Li, . PharmD. , MPH, BCOP . Associate Professor. & non-biological similar medicinal products . Cooperative European Medicines Development Course (CEMDC). 14. Appreciate the factors influencing the . adoption. . of follow-on drugs . in the everyday practice. . Guidelines. Kamali Chance, MPH, PhD, RAC. Senior Director . Head, Global . Biosimilars. Regulatory Strategy. Definition of . Biosimilarity. Biosimilar Guidelines Issuance in the EU and US. Regulation . Ms. Leah Goodman. Contents. Key Messages. An Overview - Biological Medicines and their Regulatory Framework. PhAMA Position and Recommendation on Biosimilars . An Overview - Biological Medicines and their Regulatory Framework. 2016 . Clinical Investigator . Training Course. Sue Lim, M.D.. Medical Officer. OND Therapeutic Biologics and . Biosimilars. . Staff/CDER/FDA. November . 8. , 2016. Overview of Presentation. Biological products. Guidelines. Kamali Chance, MPH, PhD, RAC. Senior Director . Head, Global . Biosimilars. Regulatory Strategy. Definition of . Biosimilarity. Biosimilar Guidelines Issuance in the EU and US. Regulation . Disclaimers. :. By 2016, 7 of the top 10 pharmaceuticals. worldwide will be biologics. ¹. Biosimilar Regulation – Around the World. U.S. Biosimilar Applications. under the BPCIA (42 U.S.C. § . 262(k)) . Moffitt Cancer Center, Director of Pharmacy (Retired). Biosimilar Drugs: . Opportunities and Issues. The Community Oncology Alliance Conference. Moving Forward on Payment Reform. April 23, 2015. Disclosures. OMIC Group Biosimilars 2014. Hyderabad India. 27-29 Oct 2014. Rodeina Challand. ChallandRodeina@prahs.com. Global Biosimilar Concept. Generic approach is not appropriate. Step-wise comparability approach. perspective. Warwick Smith. Director General BGMA & BBA. Dispensing Doctors’ Association. 20 October 2016. Stuff to cover. An introduction. Key data. Supply chain. Pricing and reimbursement. High cost generics. Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. Andrew . Karl, . Adsurgo. LLC. Richard Burdick, Elion Labs. Outline. 2. Introduction. Current. FDA Thinking/Approach. Demonstration:. . Statistical Equivalence using Sample Size and Variance Adjustment Method.